Jeil Pharma Holdings (002620) Fundamentals 2026 — P/E 7.7x, Revenue Analysis | SniperIQ
Jeil Pharma Holdings (002620) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩103.3B, trading at ₩6730.00 on the KSC. This SniperIQ fundamentals page covers Jeil Pharma Holdings's valuation (P/E 7.7x, P/B 0.3x), profitability (net margin 2.2%), revenue (₩657.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jeil Pharma Holdings's market cap?
Jeil Pharma Holdings (002620) has a market capitalization of approximately ₩103.3B, trading at ₩6730.00 on the KSC. Market cap moves with the live share price.
What is Jeil Pharma Holdings's P/E ratio?
Jeil Pharma Holdings's trailing twelve-month P/E ratio is 7.7x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jeil Pharma Holdings?
Jeil Pharma Holdings runs a net profit margin of 2.2%, a gross margin of 39.6%, and an operating margin of 1.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jeil Pharma Holdings generate?
Jeil Pharma Holdings reported revenue of ₩657.6B for fiscal year 2025, with net income of ₩14.6B and earnings per share (EPS) of 953.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jeil Pharma Holdings pay a dividend?
Jeil Pharma Holdings offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jeil Pharma Holdings financially healthy?
Jeil Pharma Holdings carries a debt-to-equity ratio of 0.53x and a current ratio of 1.22x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jeil Pharma Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jeil Pharma Holdings (002620) the key facts are: market cap ₩103.3B, P/E 7.7x, revenue ₩657.6B, 52-week range 6050-9920. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jeil Pharma Holdings's full fundamentals live
Get Jeil Pharma Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.